Eng then began a collaboration with Amylin Pharmaceutical and in a series of clinical trials, exendin-4 injected twice daily showed highly significant efficacy in Type 2 diabetic patients with lowering of HbA1c by 0.86% and modest weight loss of 1.6 kg ( 1 , 20 ).
← all excerpts
The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity.
1
—
—